USANA Health Sciences (NYSE:USNA) Share Price Breaks Above 50 Day Moving Average – Here’s Why

USANA Health Sciences, Inc. (NYSE:USNA)’s stock price passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $14.57 and traded as high as $14.90. USANA Health Sciences shares last traded at $14.7150, with a volume of 175,944 shares.

Wall Street Analysts Forecast Growth

USNA has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, September 21st. Zacks Research raised USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Wall Street Zen downgraded USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Reduce”.

USANA Health Sciences Price Performance

The stock has a fifty day moving average price of $14.57 and a 200 day moving average price of $18.10. The stock has a market capitalization of $271.93 million, a P/E ratio of -12.16, a price-to-earnings-growth ratio of 1.60 and a beta of 0.68.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. The company had revenue of $223.27 million for the quarter, compared to the consensus estimate of $235.00 million. Research analysts anticipate that USANA Health Sciences, Inc. will post 0.76 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc increased its position in shares of USANA Health Sciences by 1,472.3% during the second quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock valued at $34,000 after buying an additional 1,487 shares during the period. GAMMA Investing LLC lifted its holdings in shares of USANA Health Sciences by 689.4% in the third quarter. GAMMA Investing LLC now owns 2,763 shares of the company’s stock worth $40,000 after buying an additional 2,413 shares in the last quarter. State of Wyoming bought a new position in shares of USANA Health Sciences in the first quarter valued at approximately $57,000. GSA Capital Partners LLP bought a new position in shares of USANA Health Sciences in the second quarter valued at approximately $250,000. Finally, DGS Capital Management LLC bought a new position in shares of USANA Health Sciences in the first quarter valued at approximately $208,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.